ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
ARS Pharmaceuticals (Nasdaq: SPRY) announced it will host a conference call and webcast on November 13, 2024, at 8:00 a.m. ET to discuss its third quarter 2024 financial results and business highlights. The company's management will also participate in several upcoming investor conferences, including Guggenheim's Inaugural Healthcare Innovation Conference, Stifel Healthcare Conference, and Jefferies London Healthcare Conference. Webcasts will be available on the company's website for 30 days following each event.
ARS Pharmaceuticals (Nasdaq: SPRY) ha annunciato che ospiterà una conferenza telefonica e un webcast il 13 novembre 2024, alle 8:00 a.m. ET, per discutere i suoi risultati finanziari del terzo trimestre 2024 e i punti salienti aziendali. La direzione dell'azienda parteciperà anche a diverse conferenze per investitori in arrivo, tra cui la Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim, la Conferenza Sanitaria di Stifel e la Conferenza Sanitaria di Jefferies a Londra. Gli webcast saranno disponibili sul sito web dell'azienda per 30 giorni dopo ogni evento.
ARS Pharmaceuticals (Nasdaq: SPRY) anunció que llevará a cabo una conferencia telefónica y un webcast el 13 de noviembre de 2024, a las 8:00 a.m. ET, para discutir sus resultados financieros del tercer trimestre de 2024 y los aspectos destacados del negocio. La dirección de la empresa también participará en varias conferencias de inversores que se avecinan, incluidas la Conferencia Inaugural sobre Innovación en Salud de Guggenheim, la Conferencia de Salud de Stifel y la Conferencia de Salud de Jefferies en Londres. Los webcast estarán disponibles en el sitio web de la empresa durante 30 días después de cada evento.
ARS 제약(나스닥: SPRY)은 2024년 11월 13일 오전 8시(ET)에 전화 회의 및 웹캐스트를 개최하여 2024년 3분기 재무 결과 및 사업 하이라이트에 대해 논의할 것이라고 발표했습니다. 회사 경영진은 또한 구겐하임의 첫 번째 의료 혁신 회의, 스티펠 헬스케어 회의, 제프리의 런던 헬스케어 회의 등 여러 예정된 투자자 회의에 참석할 예정입니다. 웹캐스트는 각 이벤트 후 30일 동안 회사 웹사이트에서 제공될 것입니다.
ARS Pharmaceuticals (Nasdaq: SPRY) a annoncé qu'elle organisera un appel conférence et un webcast le 13 novembre 2024, à 8 h 00 ET, pour discuter de ses résultats financiers du troisième trimestre 2024 et des points forts de son activité. La direction de l'entreprise participera également à plusieurs conférences pour investisseurs à venir, y compris la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim, la Conférence sur la Santé de Stifel et la Conférence sur la Santé de Jefferies à Londres. Les webcasts seront disponibles sur le site web de l'entreprise pendant 30 jours après chaque événement.
ARS Pharmaceuticals (Nasdaq: SPRY) gab bekannt, dass am 13. November 2024 um 8:00 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden werden, um über die Finanzergebnisse des dritten Quartals 2024 und wichtige Geschäftsinformationen zu sprechen. Das Management des Unternehmens wird auch an mehreren bevorstehenden Investorenkonferenzen teilnehmen, darunter die Erste Gesundheitsinnovationskonferenz von Guggenheim, die Stifel Gesundheitskonferenz und die Jefferies Gesundheitskonferenz in London. Die Webcasts werden 30 Tage nach jeder Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Third Quarter Earnings Conference Call to be Held on November 13 at 8:00 a.m. ET
SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, November 13, 2024, at 8:00 a.m. ET to discuss its third quarter 2024 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event here.
In addition, ARS Pharma Management will be participating in multiple upcoming investor conferences:
- Guggenheim’s Inaugural Healthcare Innovation Conference: fireside chat on November 13, 2024, at 1:00 p.m. ET (10:00 a.m. PT)
- Stifel Healthcare Conference: presentation on November 18, 2024, at 2:25 p.m. ET (11:25 a.m. PT)
- Jefferies London Healthcare Conference: investor meetings on November 20-21, 2024
To access the live and archived webcasts for the third quarter 2024 earnings conference call and investor conferences, please visit the Events & Presentations page in the “Investors & Media” section of the Company’s website. A replay of the each of the webcasts will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® 2 mg (trade name EURneffy® in the European Union (EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contacts:
Justin Chakma, ARS Pharmaceuticals
justinc@ars-pharma.com
Alex Straus, THRUST
alex@thrustsc.com
Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
FAQ
When will ARS Pharmaceuticals (SPRY) report Q3 2024 earnings?
Which investor conferences will ARS Pharmaceuticals (SPRY) attend in November 2024?
How long will the SPRY earnings call webcast be available for replay?
